NOVARTIS (NVS) Wins Positive CHMP Opinion for Cosentyx in Polymyalgia Rheumatica
The EMA committee recommends Cosentyx for adults with PMR who fail steroids, which would make it the first IL-17A inhibitor cleared for the disease in Europe.
Novartis (NVS) said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) in polymyalgia rheumatica, a common inflammatory rheumatic disease in adults over 50. The opinion covers adults who had an inadequate response to steroids or who relapse during steroid taper. A final decision from the European Commission is expected within roughly two months.
